Colorectal Cancer, Metastatic Colorectal Cancer, Refractory Colorectal Cancer
Conditions
Keywords
Fruquintinib
Brief summary
Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we explore the real-world treatment patterns of fruquintinib in the third- or late-line setting for mCRC in six centers in China.
Interventions
DRUGFruquintinib
an oral tyrosine kinase inhibitor (TKI)
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
(1) histology-confirmed metastatic CRC (mCRC); (2) disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab; (3) fruquintinib administered as salvage treatment; (4) available clinical data.
Exclusion criteria
(1) lack of follow-up data; (2) fruquintinib administration as second-line treatment; (3) fruquintinib administration stopped after less than two cycles.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | Three years | PFS was calculated from the date of fruquintinib administration to the first observation of disease progression or death |
| OS | Three years | OS was defined as the time from fruquintinib administration to death |
| DCR | During the medication period | DCR was determined as the proportion of patients who achieved complete response, partial response or stable disease assessed at least 6 weeks after drug administration |
Countries
China
Outcome results
None listed